Salvage high-dose chemotherapy for children with extragonadal germ-cell tumours by De Giorgi, U et al.
Salvage high-dose chemotherapy for children with extragonadal
germ-cell tumours
U De Giorgi*,1, G Rosti
1, S Slavin
2, I Yaniv
3, JL Harousseau
4, R Ladenstein
5, T Demirer
6 and G Dini
7, on behalf of
the European Group for Blood and Marrow Transplantation Solid Tumours and Paediatric Disease Working
Parties
1Istituto Oncologico Romagnolo-Department of Oncology/Haematology, Santa Maria delle Croci Hospital, Ravenna, Italy;
2Department of Bone Marrow
Transplantation and Cancer Immunotherapy, Hadassah University Hospital, Jerusalem, Israel;
3Department of Paediatric Haematology Oncology,
Schneider Children’s Medical Centre of Israel, Petah Tikva, Israel;
4Department of Haematology, University Hospital, Nantes, France;
5Department of
Paediatric Haemato-Oncology, St Anna Children’s Hospital, Vienna, Austria;
6Department of Haematology/Oncology and Bone Marrow Transplant Unit,
Ankara University Medical School, Ankara, Turkey;
7Department of Paediatric Haematology Oncology, Institute G Gaslini, Genoa, Italy
We reviewed the European Group for Blood and Marrow Transplantation (EBMT) experience with salvage high-dose chemotherapy
(HDC) in paediatric patients with extragonadal germ-cell tumour (GCT). A total of 23 children with extragonadal GCT, median age
12 years (range 1–20), were treated with salvage HDC with haematopoietic progenitor cell support. The GCT primary location was
intracranial site in nine cases, sacrococcyx in eight, retroperitoneum in four, and mediastinum in two. In all, 22 patients had a
nongerminomatous GCT and one germinoma. Nine patients received HDC in first- and 14 in second- or third-relapse situation. No
toxic deaths occurred. Overall, 16 of 23 patients (70%) achieved a complete remission. With a median follow-up of 66 months
(range 31–173 months), 10 (43%) are continuously disease-free. Of six patients who had a disease recurrence after HDC, one
achieved a disease-free status with surgical resection followed by chemotherapy and radiotherapy. In total, 11 patients (48%) are
currently disease-free. Eight of 14 patients (57%) with extracranial primary and three of nine patients (33%) with intracranial primary
GCT are currently disease-free. HDC induced impressive long-term remissions as salvage treatment in children with extragonadal
extracranial GCTs. Salvage HDC should be investigated in prospective trials in these patients.
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Germ-cell tumours (GCTs) represent 3% of all paediatric
neoplasms (Ries et al, 2003). The most common primary sites
are the ovary (26%), the coccyx (24%), the testis (18%), the brain
(18%), the mediastinum (4%) and the retroperitoneum (4%).
Therefore, germ cell malignancies arising from extragonadal
primary site represent nearly 50–60% of all GCTs in children
(Gobel et al, 2000). Extragonadal primary location coupled with
high serum levels of alpha-fetoprotein (AFP) (more than
10000ngml
 1) at diagnosis are the most unfavourable prognostic
factors for these children (Mann et al, 1989; Marina et al, 1992;
Baranzelli et al, 1999, 2000; Schneider et al, 2000; Lo Curto et al,
2003). Moreover, the prognosis of extragonadal GCT is signifi-
cantly influenced by the histological differentiation, with the
secreting GCTs (embryonal carcinoma, yolk sac tumour, chorio-
carcinoma) and immature teratoma having a higher risk of relapse
after primary treatment than germinoma/dysgerminoma and
mature teratoma (Gobel et al, 1999).
Conventional treatment for children with advanced GCT
consists of cisplatin-based chemotherapy followed by surgical
resection of residual disease, if necessary (Rescorla and Breitfeld,
1999). More than 80% of these children are cured with standard
treatments (Mann et al, 2000; Kramarova et al, 2001). Very limited
data are available concerning therapeutic options and long-term
results of recurrent GCTs in children (Gobel et al, 2002).
High-dose chemotherapy (HDC) with haematopoietic progenitor
cell support (HPCS) is a therapeutic option mainly investigated
in adult patients with GCT either as first-line or salvage setting
(De Giorgi et al, 2002). Preliminary experiences with HDC in
children resulted in long-term remissions in those patients in whom
a clinical complete remission (CR) could be achieved prior to HDC
(Gobel et al, 2002). Subsequently, in children, HDC with HPCS has
been mainly investigated as first-line treatment, or for consolida-
tion therapy after primary standard-dose chemotherapy.
To better characterise the role of HDC with HPCS as salvage
therapy for children with extragonadal GCT, the large database
of the patients registered with the European Group for Blood
and Marrow Transplantation (EBMT) was reviewed. This report
describes the EBMT experience of salvage HDC in 23 children with
extragonadal GCT.
MATERIALS AND METHODS
Data collection
The 23 relapse children analysed in this study belong to a cohort of
160 paediatric and adult patients with a diagnosis of extragonadal
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sGCT, who have been registered with the EBMT from December
1987 to December 1999. The date of last follow-up was July 2003.
Germ-cell tumours were classified as seminoma/germinoma,
embryonal carcinoma, choriocarcinoma or mixed GCTs, mature
or immature teratoma and yolk sac tumour according to the World
Health Organization classification. Patients with histologically
undifferentiated tumours with markedly elevated serum markers,
who were treated according to GCT protocols, are included in
this report. We reviewed the registration details of these patients.
The reporting physicians were contacted and asked to provide
further information on primary tumour site and extent of
disease, histology, tumour markers, initial treatment, second-line
chemotherapy, HDC drugs and toxicities, follow-up and data on
possible secondary neoplasm. For data collection, a standardised
questionnaire was sent to each centre. All patient data were
obtained in an anonymous manner. Of 160 registered cases, 120
(75%) questionnaires were returned. Among these 120 patients,
we analysed 23 cases of children with a diagnosis of extragonadal
GCTs treated with salvage HDC, including three of nine cases with
intracranial GCT, aged 15, 18 and 19 years, respectively. As this is
a report of registry data, there are cases where information is
incomplete, as indicated in the tables.
Definitions
Tumour response was classified as follows: CR was defined as a
complete disappearance of all clinical, radiological and biochemical
evidence of disease, with normalisation of the tumour markers,
beta-human chorionic gonadotropin (HCG) and/or AFP and/or
lactate dehydrogenase (LDH), for at least a 1-month duration. A
partial response (PR) was defined as a decrease in 50% or more of
the sum of the products of perpendicular diameters of measurable
disease, lasting at least for 1 month. If elevated markers were the
only evidence of disease, a decrease of 90% or greater was required
for a PR. In addition, reduction of the size of a tumour lesion and
normalisation of previously elevated tumour markers was
considered a partial remission with tumour marker normalisation
(PR ), whereas a reduction X50% in the sum of the perpendicular
diameters of measurable disease plus a tumour marker decrease
for at least 1 month, but without complete normalisation, was
considered a marker positive partial remission (PRþ). Stable
disease (SD) was defined as a decrease o50% or an increase
o25% in bidimensional tumour measurements or stable tumour
marker levels. Progressive disease (PD) was defined as either
residual lesions increasing in size or as the occurrence of new
lesions and/or elevation of tumour markers at repeated controls.
Patient characteristics
Details at diagnosis of the 23 patients are listed in Table 1. The
median age was 7 years (range, 1–19). In all, 14 patients were
males and nine were female. Nine patients had primary CNS
(pineal/pituitary area), eight sacrococcygeal, four retroperitoneal
and two mediastinal GCT. A total of 22 patients had a
nongerminoma (three embryonal carcinoma, three yolk sac
tumour, two immature teratoma, one choriocarcinoma, four CNS
lesions with serum tumour marker increase, nine mixed GCT) and
one germinoma. Most commonly, patients received cisplatin-based
chemotherapy as first-line treatment. Table 1 summarises the
characteristics of patients at diagnosis, primary treatment and
response.
Salvage treatment
In all, 13 patients received a second-line standard-dose che-
motherapy given at first relapse/progression, while one patient
received even a third-line standard-dose chemotherapy at second
relapse/progression. Nine patients received salvage HDC in first-,
13 in second- and one in third-relapse situation. Nine (39%)
patients received an induction and/or mobilising regimen before
Table 1 Patient characteristics at diagnosis and treatments before high-dose chemotherapy
No. Age Sex Primary location Histology Increased markers Metastatic sites Primary treatment Response
1 1 M Sacr EC, IT AFP¼794 Lung RPTR; Cis, Vbl, Bl, VP16, Ifo (Adj) CR
2 1 F Sacr NSGCT AFP¼22250 Liver, B RPTR; Cis, Vbl, Bl, VP16, Ifo, AcD, Cy; PRLM PR+
3 13 M CNS Unknown AFP¼3710 None Carbop, VP16, Ifo PD
4 15 F CNS Germin None None RT-CNS; Cis, Vbl, Bl, VP16, Ifo CR
5 1 F Sacr NSGCT AFP¼54290, LDH¼931 None PPTR; CT PR+
6 1 F Sacr NSGCT AFP¼13750 Bone Cis, Vbl, Bl CR
7 13 M CNS MT, YST AFP¼305 None Carbop, VP16, Bl PR+
8 14 M CNS Unknown AFP/HCG exact values unknown None Cis, VP16, Bl; RT-CNS CR
9 1 M Sacr YST AFP¼104000 Retr, Liver Cis, Vcr, Ifo, Carbop, Vbl, Bl, PR 
10 11 M CNS EC AFP¼43; HCG¼142 None RT-CNS; Cis, Vcr, VP16, Cy PR 
11 13 M Med NSGCT AFP¼6100; HCG¼920 None Carbop, Vbl, Bl, AcD PR+
12 6 F Sacr EC, YST HCG¼18042; LDH¼999 Med, CNS, Lung, B Cis, Vcr, Mtx, Bl, AcD, Cy, VP16 PD
13 18 M CNS EC, MT AFP¼416; HCG¼30; LDH¼1149 None RT-CNS PR 
14 7 M CNS Unknown AFP¼145, HCG¼53 None RT-CNS CR
15 1 F Sacr EC AFP¼46100 None PPTR; Carbop, Cy, AcD, Vbl, Bl CR
16 9 M Retr NSGCT Unknown None RPTR; Vcr, AcD (Adj) CR
17 12 M CNS Unknown AFP¼339 None CT; RT-CNS PR+
18 1 F Sacr YST AFP¼30947, LDH¼828 Retr, Liver Cis, Vbl, Bl, VP16, Ifo, AcD CR
19 19 M CNS CC HCG¼40400 Lung CT; RT-CNS PD
20 11 M Med EC, YST None None RPTR; Cis, VP16, Bl (Adj) CR
21 7 M Retr NSGCT Unknown None PPTR; Cis, VP16, Bl PR+
22 4 F Retr YST AFP¼278000, LDH¼1786 Liver Cis, Vbl, Bl, VP16, Ifo CR
23 1 F Retr EC AFP¼148600 None PPTR; Cis, VP16, Bl PR+
M, male; F, female; Sacr, sacrococcix; CNS, central nervous system; Med, mediastinum; Retr, retroperitoneum; B, bone; IT, immature teratoma; MT, mature teratoma; YST, yolk
sac tumour; EC, embryonal carcinoma; CC, choriocarcinoma; Germin, germinoma; NSGCT, nonseminomatous germ-cell tumour (not furthermore specified); AFP, alpha-
fetoprotein (ngml
 1); HCG, human choriogonadotropin (IUl
 1); RPTR, radical primary tumour resection; PPTR, partial primary tumour resection; PRLM, partial resection liver
metastases; Cis, cisplatin; Vbl, vinblastin; Bl, bleomycin; VP16, etoposide; Ifo, ifosfamide; AcD, actinomycin D; Cy, cyclophosphamide; Carbop, carboplatin; Vcr, vincristine; Mtx,
methotrexate; CT, chemotherapy (schedule/drugs not available); RT, radiotherapy; Adj, adjuvant; CR, complete remission; PR , marker-negative partial remission; PR+, marker-
positive partial remission; SD, stable disease; PD, progressive disease.
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slate-intensification HDC. The response to the last chemothera-
peutic regimen before the induction regimen was CR in four cases,
PR  in two and PRþ in three (Table 3). Then, the policy of EBMT
centres was to use late-intensification HDC only in chemosensitive
disease. In total, 14 (61%) patients were treated with upfront
salvage HDC. The response to the last chemotherapeutic regimen
before upfront HDC was PRþ in three cases, SD in one, PD in
three, while six patients underwent HDC at the time of relapse after
a previous CR or PR  (sensitive relapse) (Table 3). The salvage
HDC regimens for extragonadal GCT patients were adapted based
on the chemotherapeutic regimens given as initial therapy, and the
salvage HDC protocols used in each centre for recurrent tumours
in children, including drugs proven to be active in GCT. A total of
18 patients received one course of HDC, four underwent two
courses; in one case three courses were given. The most commonly
used HDC regimen was Carbopec, including carboplatin, etoposide
and cyclophosphamide (n¼7, 24%). High-dose chemotherapy
regimens are listed in Table 2. Haematopoietic support consisted
of peripheral blood progenitor cells (PBPCs) in 19 courses,
autologous bone marrow transplantation (ABMT) in nine, both
of them in one. Table 3 summarises the salvage HDC treatments
and results.
Statistical analysis
Descriptive statistics are presented as the median and range.
Duration of followup and survival in this analysis were calculated
based on the date of the first day of salvage chemotherapy until the
date of last contact, if the patient was still alive, or until the date of
death. Probabilities of disease-free survival and overall survival
were determined using the Kaplan–Meier product limit method
(Kaplan and Meier, 1958).
RESULTS
Toxicity
Toxicity data were fully assessable for 26 (90%) of 29 HDC cycles
delivered. No treatment-related deaths occurred after HDC.
The median time to recovery of an absolute neutrophil count
4500ml
 1 and a platelet count 420000ml
 1, respectively, was
10.5 days (range, 6–22) and 10.5 days (range, 0–48). The median
number of transfusions of red blood cell and platelet bags was 4
(range, 1–8) and 6.5 (range, 1–30), respectively. Fever occurred in
21 courses (81%), with an overall median duration of 3 days
(range, 0–13). The number of HDC courses with episodes of
clinically documented infections was 13 (50%).
The following nonhaematological side effects were the most
relevant: grade X3 stomatitis was reported in nine courses, grade
X3 pulmonary toxicity in two, grade 3 peripheral neurotoxicity in
one, grade 3 anorexia in one and psychosis in one. Veno-occlusive
disease occurred in two patients (pt. no. 8 and no. 16, Table 3),
both received the HDC regimen, including carboplatin, etoposide,
thiotepa and melphalan. Neither renal nor cardiac toxicity was
observed. No patients developed myelodysplasia or secondary
neoplasms after HDC.
Response and survival
Overall, 16 (70%) patients achieved a CR. Of these patients, 14
obtained a radiological CR after HDC, while the other two with
radiological PR  obtained a CR with post-HDC resection of
residual masses and radiotherapy in one case. Results are
presented in detail in Table 3.
The median follow-up period for all patients was 31 months
(range, 3–173 months) and 66 months (range, 31–173) for
surviving patients. Of 23 patients, 10 (43%) are continuously
disease-free. Of six patients who had a disease recurrence after
HDC, one underwent further surgery, chemotherapy and radio-
therapy, and achieved a disease-free status. In total, 11 patients
(48%) are currently disease-free (Figure 1).
The continuously disease-free status was achieved in four of
nine patients (44%) with chemosensitive disease treated with late-
intensification HDC, in four of six patients (67%) with sensitive
relapse, who underwent upfront HDC, and in two of eight patients
(25%) with PRþ or SD, or PD, receiving upfront HDC (Table 3).
Eight of 14 patients (57%) with extracranial primary GCT (five
of eight patients (62%) with sacrococcygeal, two of four patients
(50%) with retroperitoneal and one of two patients (50%) with
mediastinal primary GCT) and three of nine patients (33%) with
intracranial primary GCT are currently alive disease-free.
Figure 2 illustrates the outcome of patients with extragonadal
GCT, according to the time of relapse. The 2-year overall survival
rates for first relapsing patients and second–third relapsing
patients were 78 and 43%, respectively.
Table 2 High-dose chemotherapy regimens
Abbreviation Chemotherapeutic drugs
No. HDC
courses
CarboPEC Carboplatin 250–350mgm
 2 4 days or dosed with Calvert formula with AUC¼7 (lower dosed used)
Etoposide 250–400mgm
 2 4 days 7
Cyclophosphamide 1.6 gm
 2 4 days
CE Carboplatin 250–500mgm
 2 3–4 days or dosed with Calvert formula with AUC¼7 (lower dosed used) 5
Etoposide 250–400mgm
 2 3–4 days
TE Thiotepa 300mgm
 2 3 days 5
Etoposide 250–300mgm
 2 3 days
CarboPETM Carboplatin 250–350mgm
 2 3–4 days or dosed with Calvert formula with AUC¼7 (lower dosed used)
Etoposide 250–400mgm
 2 3–4 days 2
Thiotepa 200–250mgm
 2 2–3 days
Melphalan 80–100mgm
 2 1 day
Other regimens HD-CyC¼high-dose cyclophosphamide 7gm
 2 (n¼2); CM¼cyclophosphamide/melphalan (n¼2); TM¼thiotepa/melphalan
(n¼1); TC¼thiotepa/cyclophasphamide (n¼1); ICE¼ifosfamide/carboplatin/etoposide (n¼1); HD-PEC¼cisplatin/etoposide/
cyclophosphamide (n¼1); CarboPTC¼carboplatin/thiotepa/cyclophosphamide (n¼1); not available (n¼1)
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sDISCUSSION
Children with relapsing/progressing extragonadal GCT are char-
acterised by a poor prognosis, with a salvage rate in the first
relapse in the range of 40–45% (Marina et al, 1992; Baranzelli et al,
1999; Sawamura et al, 1999; Gobel et al, 2000; Mann et al, 2000;
Schmugge et al, 2000).
According to extragonadal primary location, histology and the
site of recurrence/progression, the salvage strategies are different.
Standard-dose cisplatin- or carboplatin-based chemotherapy is
the conventional treatment for most of these patients. In patients
with local recurrence of sacrococcygeal GCT, the surgical complete
resection represents the cornerstone of the salvage treatment,
while chemotherapy is employed in recurrent inoperable and
metastatic disease (Schneider et al, 2001). In patients with
recurrent CNS GCTs, chemotherapy alone or combined with
radiotherapy has to be considered, if feasible (Sawamura et al,
1999; Kellie et al, 2004).
In children with recurrent mediastinal or retroperitoneal
primary GCT, the salvage strategy consists of chemotherapy
followed by resection of residual masses, if necessary (Gobel et al,
2000). High-dose chemotherapy is currently investigated as a
possible option for high-risk and recurrent CNS GCTs, and is used
on an individual basis as salvage therapy for children with other
extragonadal germ-cell malignancies (Calaminus and Patte, 2002;
Cushing et al, 2004; Kellie et al, 2004; Modak et al, 2004).
Table 3 Salvage high-dose chemotherapy for children with extragonadal germ-cell tumour
No.
T. to
first
Rel/PD
(mo)
Second-line
standard-dose
chemotherapy
before HDC
(response)
T. to
second
Rel/PD
(mo)
HDC
setting
(no. Rel)
Induction
regimen
(response)
Status
before
HDC
Sites of
disease
before
HDC
HDC
regimen (no.
cycles) Response
Further
therapies
(response)
DFS
(mo)
OS
(mo)
1 4 None NA 1st Rel Carbop, Vbl, Bl,
Vcr, AcD, Adr,
Cy(CR)
CR NED CarboPEC (1) CR Surg, CT, RT (CR) 21 173+
2 10 None NA 1st Rel None SR Liver, B PEC (1), CE (1) CR None 77+ 77+
3 NA None NA 1st Rel None PD CNS TE (1) PT RT-CNS (Unk) 0 12
4 11 Cis, VP16, Ifo, RT-CNS
(CR)
19 2
nd Rel None SR CNS CE (1) CR RT-CNS (Adj) 73+ 73+
5 9 None NA 1st Rel CT (PR–), STRR
(CR)
CR NED CarboPEC (1) CR None 73+ 73+
6 7 Cis, VP16, Ifo (PR–) 14 2nd Rel Ifo, Adm (PR–) PR– Unk TE (1) PR  RRRD (CR) 68+ 68+
7 4 Carbopl, VP16, RT-CNS
(SD)
2 2nd Rel None SD CNS HD-Cyc (2) PD CT (PD) 0 3
8 16 None NA 1st Rel Cis, Vcr, Ifo (CR) CR NED CarboPETM
(1)
CR Unk (Unk) Unk 51
9 7 Carbop, Vcr, AcD, Adr
(PR+)
8 2nd Rel None PR+ Sacr,
Retr,
Liver
CarboPTC (1) PD None 0 5
10 5 None NA 1st Rel None SR CNS CM (1) CR None 66+ 66+
11 2 None NA 1st Rel VP16, Ifo (PR-),
MTRR (CR)
CR NED TE (1) CR None 63+ 63+
12 1 Cis, Vcr, Bl, VP16, Ifo
(PD)
NA 2nd Rel None PD Med,
CNS,
Lung, B
CarboPEC (1) PD None 0 3
13 2 Cis, VP16, Bl (PR ) 8 2nd Rel RT-CNS, Cis, VP16,
Ifo (PT)
PT CNS CarboPEC (1) PT Surg (CNS) 0 16
14 62 Cis, BCNU, VP16, Cy
(PR )
6 2nd Rel None SR CNS CM (1) CR RT-CNS, CT (PD) 5 5
15 9 Cis, VP16, Ifo (CR) 9 2nd Rel None SR Unk TE (1) CR None 63+ 63+
16 4 Ifo, VP16, Vcr, AcD, Cy
(CR)
41 2nd Rel Carbopl, VP16, Ifo,
Cy (CR)
CR NED CarboPETM
(1)
CR Unk (PD) Unk 29
17 18 Carbop, VP16, Ifo, Cis,
Vbl (PD)
NA 2nd Rel None PD CNS TE (1) CR None 40+ 40+
18 8 Cis, VP16, Vcr (PR+) 6 2nd Rel Carbop, Vbl, Bl
(PT)
PT Lung CarboPEC (1) CR RT-Lung 9 11
19 1 Cis, VP16, Bl, Ifo (PR+) 3 2nd Rel None PR+ CNS CarboPEC (2) CR RT-CNS, CT (PD) 6 8
20 9 None NA 1st Rel None SR Unk ICE (1), TC (1) PD CT, Surg (PD) 0 15
21 3 Cis, Vcr, Mtx, Bl, AcD, Cy
(PR+)
6*(5**) 3rd Rel None PR+ Retr CE (3) PR  RRRD (CR) 34+ 34+
22 26 None NA 1st Rel Carbop, VP16, Ifo
(CR)
CR NED TM (1) CR None 31+ 31+
23 10 Cis, VP16, Bl (PR+) 8 2nd Rel None PR+ Retr Unk (1) PR+ None 0 5
*After 6 months second Rel, treated with third-line standard-dose chemotherapy with Ifo,Vbl, VP16 (PR+); **after 5 months 3rd Rel/PD. Abbreviations: T.to first or second Rel/
PD, Time to first or second relapse/progressive disease; HDC, high-dose chemotherapy; mo, months; NA, not applicable; Sacr, sacrococcix; CNS, central nervous system; Retr,
retroperitoneum; Med, mediastinum; B, bone; NED, not evidence of disease; Unk, unknown; IT, immature teratoma; MT, mature teratoma; YST, yolk sac tumour; EC, embryonal
carcinoma; Germ, germinoma; CC, choriocarcinoma; AFP, alpha-fetoprotein (ngml
 1); HCG, human choriogonadotropin (IUl
 1); MTRR, mediastinal tumour radical resection;
STRR, sacrococcigeal tumour radical resection; RRRD, radical resection of residual disease; Cis, cisplatin; Vbl, vinblastin; Bl, bleomycin; VP16, etoposide; Ifo, ifosfamide; ActD,
actinomycin D; Cy, cyclophosphamide; Carbop, carboplatin; Vcr, vincristine; BCNU, bendamustine; Mtx, methotrexate; Adm, adriamycin; CT, chemotherapy (schedule/drugs not
available); RT, radiotherapy; Adj, adjuvant; CR, complete remission; PR , marker-negative partial remission; PR+, marker-positive partial remission; SD, stable disease; PD,
progressive disease; PT, persistent tumour with response not evaluable; SR, sensitive relapse (indicating patients relapsing after a previous CR orP R   and receiving frontline HDC
without induction regimens). For abbreviations of HDC regimens, see Table 2.
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sFew series with salvage chemotherapy for relapse GCT patients
with extragonadal primary are reported in literature. The largest
experience with different salvage standard-dose chemotherapeutic
approaches, more often including cisplatin-based chemotherapy,
in relapse patients with sacrococcygeal GCT showed 10 of the
22 patients (45%) disease-free at a median followup of 56 months
(Schneider et al, 2001). Other authors investigated the use of
salvage treatments including standard-dose chemotherapy and/or
HDC in patients with relapsed CNS GCT (Calaminus and Patte,
2002; Kellie et al, 2004). Overall, in these highly heterogeneous
experiences, long-term remissions were obtained in nearly 25–
50% of cases. Another report presented the largest series of
patients with recurrent or progressive CNS GCTs treated with
thiotepa-based HDC. No toxic deaths occurred. Out of the 21
patients, 11 (52%) achieved long-term disease-free survival.
Results were clearly better for germinomas (seven of nine patients,
78%, disease-free continuously), than for nongerminomatous
GCTs (four of 12 patients, 33%, long-term disease-free) (Modak
et al, 2004). Recently, a regimen including high doses of cisplatin
has been compared to standard-dose chemotherapy as primary
treatment in a randomised study in 299 children with high-risk
GCTs, including 165 extragonadal GCTs. Chemotherapy has
consisted of bleomycin 15Um
 2, etoposide 500mgm
 2 and either
cisplatin 200mgm
 2 (high-dose arm) or cisplatin 100mgm
 2
(standard-dose arm). The overall survival has been similar in both
regimens; treatment-related deaths and grade 3–4 toxicities have
been more common with HDC. As a consequence, the arm
including high-dose cisplatin is not being recommend for
paediatric patients as first-line treatment (Cushing et al, 2004).
In this report, we have presented the results of the EBMT
experience with HDC as salvage treatment for children with
extragonadal GCT. To the best of our knowledge, this is the largest
reported experience with HDC in these patients as salvage setting.
Only one patient with germinoma (pt. no. 4 in the tables) was
included in this analysis. Nine patients received HDC in first- and
14 in second- or third-relapse situation. All extracranial GCT
patients but one were chemosensitive before HDC, while two
intracranial GCT patients were chemorefractory. With a median
followup of 66 months (range, 31–173), of 23 extragonadal GCT
patients who received salvage HDC, 10 (43%) are disease-free
continuously. Since another patient with disease recurrence
achieved a disease-free status after further chemotherapy, 11
extragonadal GCT patients (48%) are currently disease-free: eight
of 14 patients (57%) with extracranial primary GCT, and three of
nine patients (33%) with intracranial primary GCT. Therefore,
HDC could be a possible option as salvage treatment for
extracranial GCTs. Our results for intracranial GCTs, including
only one germinoma, are similar to those of other major
experiences for nongerminomatous CNS GCTs (Modak et al,
2004). The 2-year overall survival rates for first relapsing patients
and second–third relapsing extragonadal GCT patients were
clearly different: 78 and 43%, respectively. In our experience,
HDC induces a high rate of long-term remissions even as third-line
treatment. An induction regimen before HDC was given in nine
patients, five (56%) are continuously disease-free. Multiple HDC
courses were given in five cases as upfront salvage treatment, in
four with PBPC support. Of these five children, three died of
disease. Therefore, either an induction regimen before HDC or
multiple upfront HDC courses were not associated with improved
results (Table 3).
In the EBMT experience, no toxic deaths occurred, and the two
cases of VOD were reported in the only two patients treated with
the four-drug HDC regimen, including carboplatin, etoposide,
thiotepa and melphalan. The tolerability of HDC could be related
to the HDC regimens used. Most commonly, patients received
carboplatin- or etoposide-based HDC regimens, and only in one
case high-dose cisplatin was given (Table 2). Moreover, no patients
developed myelodysplasia or secondary neoplasms after receiving
HDC in our short experience, even though an increased risk of
acute myelogenous leukaemia was reported in children with GCT
after standard-dose chemotherapy (Schneider et al, 1999).
In conclusion, in the EBMT experience, HDC with HPCS
induced impressive long-term remissions as salvage treatment in
children with extragonadal extracranial GCTs. Salvage HDC should
be investigated in prospective trials in these patients. New
strategies should be considered for salvage treatment of patients
with CNS GCT.
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